↓ Skip to main content

Recent developments in multiple sclerosis therapeutics

Overview of attention for article published in BMC Medicine, December 2009
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (83rd percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

blogs
1 blog

Citations

dimensions_citation
17 Dimensions

Readers on

mendeley
86 Mendeley
Title
Recent developments in multiple sclerosis therapeutics
Published in
BMC Medicine, December 2009
DOI 10.1186/1741-7015-7-74
Pubmed ID
Authors

Rebecca I Spain, Michelle H Cameron, Dennis Bourdette

Abstract

Multiple sclerosis, the most common neurologic disorder of young adults, is traditionally considered to be an inflammatory, autoimmune, demyelinating disease of the central nervous system. Based on this understanding, the initial therapeutic strategies were directed at immune modulation and inflammation control. These approaches, including high-dose corticosteroids for acute relapses and long-term use of parenteral interferon-beta, glatiramer acetate or natalizumab for disease modification, are at best moderately effective. Growing evidence supports that, while an inflammatory pathology characterizes the early relapsing stage of multiple sclerosis, neurodegenerative pathology dominates the later progressive stage of the disease. Multiple sclerosis disease-modifying therapies currently in development attempt to specifically target the underlying pathology at each stage of the disease, while avoiding frequent self-injection. These include a variety of oral medications and monoclonal antibodies to reduce inflammation in relapsing multiple sclerosis and agents intended to promote neuroprotection and neurorepair in progressive multiple sclerosis. Although newer therapies for relapsing MS have the potential to be more effective and easier to administer than current therapies, they also carry greater risks. Effective treatments for progressive multiple sclerosis are still being sought.

Mendeley readers

The data shown below were compiled from readership statistics for 86 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 2 2%
Uruguay 1 1%
France 1 1%
Brazil 1 1%
Colombia 1 1%
Unknown 80 93%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 17 20%
Researcher 13 15%
Student > Ph. D. Student 13 15%
Student > Master 8 9%
Professor > Associate Professor 8 9%
Other 22 26%
Unknown 5 6%
Readers by discipline Count As %
Medicine and Dentistry 37 43%
Agricultural and Biological Sciences 15 17%
Biochemistry, Genetics and Molecular Biology 6 7%
Neuroscience 5 6%
Computer Science 3 3%
Other 13 15%
Unknown 7 8%

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 January 2011.
All research outputs
#503,327
of 3,685,110 outputs
Outputs from BMC Medicine
#611
of 1,020 outputs
Outputs of similar age
#14,004
of 85,546 outputs
Outputs of similar age from BMC Medicine
#58
of 85 outputs
Altmetric has tracked 3,685,110 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,020 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 20.0. This one is in the 38th percentile – i.e., 38% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 85,546 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 85 others from the same source and published within six weeks on either side of this one. This one is in the 31st percentile – i.e., 31% of its contemporaries scored the same or lower than it.